Vai ai contenuti. | Spostati sulla navigazione | Spostati sulla ricerca | Vai al menu | Contatti | Accessibilità

| Crea un account

Frayle Salamanca, Helena (2009) HPV e carcinoma della cervice uterina. [Tesi di dottorato]

Full text disponibile come:

[img]
Anteprima
Documento PDF
2183Kb

Abstract (inglese)

The identification of Human Papillomavirus (HPV) as a necessary cause for the development of cervical cancer and the detection of the different HPV oncogenic types through molecular techniques has made it possible the study of new strategies for the screening (triage, primary test) that can permit to identify with greater accuracy women at risk to develop a high-grade lesion or an invasive carcinoma. Given this information, we have performed search and typing of HPV sequences for triage of women with ASC-US diagnosis in a multicentric study that has involved five screening centres of the Veneto region to evaluate sensitivity and specificity of HPV test in comparison to the Pap test repetition or colposcopy . The use of HPV test as a primary screening test is the object of the NTCC (New Technologies for Cervical Cancer) randomized trial. It has been conducted on 95.000 women enrolled from 9 cervical screening programmes in Italy; the study has the goal to evaluate the efficacy of HPV test, in comparison to conventional Pap test, in detecting high risk lesions.
We also conducted a study of type-specific prevalence in invasive carcinomas of the uterine cervix.
The results show that the HC2 test is more sensitive and more specific than colposcopy and or Pap test for the triage of women with an ASC-US diagnosis.
In the NTCC study the HC2 test showed greater sensitivity compared to Pap test but lower specificity; it has been observed that increasing the cut-off value from 1 to 2 pg/ml the test shows better specificity maintaining comparable sensitivity. In both studies women with a negative HC2 test have shown a very low risk to develop high grade lesions.
The typing results, in all the studies, pointed out HPV 16 as the most frequent type and its elevated association with high-grade lesions.
Analyzing HPV 16 variants, it has emerged that most of the high grade lesions and cervical carcinomas are caused by the European variant T350G (L83V).
The technical aspects to consider for HPV search and typing are: the method of specimen collection, set of primers and typing method. The different strategies used have shown peculiar characteristics of sensitivity and specificity on identifying the different HPV types, and the use of a strategy with multiple methods has allowed, in both studies, to type more than 90% of the HC2+ specimens. All the typing methods have shown an elevated reliability in the detection of HPV 16 and HPV 18.

Abstract (italiano)

L’identificazione del Papillomavirus Umano (HPV) come causa necessaria per lo sviluppo del carcinoma della cervice uterina e la rilevazione dei diversi tipi di HPV con diverso potenziale oncogeno mediante tecniche molecolari hanno reso possibile lo studio di nuove strategie nello screening (triage, test primario) basate su test molecolari che possono permettere di individuare con maggiore accuratezza le donne a rischio di sviluppare una lesione di alto grado o un carcinoma invasivo. Con questa informazione abbiamo effettuato la ricerca e la tipizzazione di sequenze HPV in diverse casistiche: come triage delle donne con diagnosi di ASC-US in uno studio multicentrico che ha coinvolto i servizi di screening di cinque ULSS del Veneto per valutare sensibilità e specificità del test HPV rispetto alla ripetizione del Pap test o alla colposcopia. L’utilizzo del test HPV nello screening come test primario è invece l’oggetto dello studio Nuove Tecnologie per lo screening del Carcinoma Cervicale (NTCC). Si tratta di un trial multicentrico randomizzato su 95.000 donne, in 9 centri di screening in Italia, il cui principale obiettivo è valutare se, rispetto al Pap test tradizionale, il test per la ricerca dei tipi ad alto rischio dell’HPV (HC2, Digene) permette di migliorare l’efficacia dello screening. Vengono qui presentati i dati di tipizzazione dei campioni HC2 positive delle donne arruolate a Padova. È stato condotto anche uno studio di valutazione della prevalenza tipo-specifica in carcinomi invasivi della cervice uterina.
I risultati mostrano che il test HC2 nello studio ASC-US è più sensibile e più specifico rispetto alla colposcopia e alla ripetizione del Pap test.
Nello studio NTCC il test HC2 ha mostrato una sensibilità più alta del Pap test ma una minore specificità; si è visto che aumentando il valore soglia da 1 a 2pg/ml migliora la specificità mantenendo una buona sensibilità.
In entrambi gli studi le donne con un risultato negativo al test HC2 hanno mostrato un rischio molto basso di sviluppare lesioni di alto grado.
Per quanto riguarda la tipizzazione i risultati indicano, in tutte le casistiche, l’HPV 16 come tipo più frequente e una sua elevata associazione con lesioni di alto grado e carcinomi.
Analizzando le varianti virali dei campioni HPV 16 è emerso che la maggioranza delle lesioni di alto grado e i carcinomi cervicali sono associati alla variante virale europea T350G (L83V).
Gli aspetti tecnici da considerare per la ricerca e la tipizzazione dell’HPV sono tipo e metodo di prelievo e conservazione del campione, set dei primers utilizzati, metodo di tipizzazione. Le diverse strategie da noi impiegate hanno mostrato caratteristiche peculiari di sensibilità e specificità nell’identificare i tipi di HPV, e va sottolineato che l’utilizzo di una strategia con più di una metodica ha permesso, in entrambi gli studi, di tipizzare più del 90% dei campioni. Tutti i metodi di tipizzazione hanno mostrato un’elevata affidabilità nella rilevazione di HPV 16 e HPV 18.

Statistiche Download - Aggiungi a RefWorks
Tipo di EPrint:Tesi di dottorato
Relatore:Del Mistro, Annarosa
Dottorato (corsi e scuole):Ciclo 21 > Corsi per il 21simo ciclo > ONCOLOGIA E ONCOLOGIA CHIRURGICA
Data di deposito della tesi:30 Gennaio 2009
Anno di Pubblicazione:30 Gennaio 2009
Parole chiave (italiano / inglese):HPV, Test HC2, Line Blot
Settori scientifico-disciplinari MIUR:Area 06 - Scienze mediche > MED/06 Oncologia medica
Struttura di riferimento:Dipartimenti > Dipartimento di Scienze Oncologiche e Chirurgiche
Codice ID:1781
Depositato il:30 Gen 2009
Simple Metadata
Full Metadata
EndNote Format

Bibliografia

I riferimenti della bibliografia possono essere cercati con Cerca la citazione di AIRE, copiando il titolo dell'articolo (o del libro) e la rivista (se presente) nei campi appositi di "Cerca la Citazione di AIRE".
Le url contenute in alcuni riferimenti sono raggiungibili cliccando sul link alla fine della citazione (Vai!) e tramite Google (Ricerca con Google). Il risultato dipende dalla formattazione della citazione.

De Villiers EM, Fauquet C, Broker TR, Bernard HU, Zur Hausen H. Classification of papillomaviruses. Virology. 2004; 324 (1): 17-27. Review. Cerca con Google

Doorbar J, Ely S, Sterling J, McLean C, Crawford L. Specific interaction between HPV-16 E1-E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network. Nature. 1991; 352 (6338): 824-7. Cerca con Google

Wilson VG, West M, Woytek K, Rangasamy D. Papillomavirus E1 proteins: form, function, and features. Virus Genes. 2002; 24 (3): 275-90. Review. Cerca con Google

Wilson R, Fehrmann F, Laimins LA. Role of the E1-E4 protein in the differentiation-dependent life cycle of human papillomavirus type 31. J Virol. 2005: 79 (11): 6732-40. Cerca con Google

Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002; 2 (5): 342-50. Review. Cerca con Google

Ashrafi GH, Haghshenas MR, Marchetti B, O'Brien PM, Campo MS. E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I. Int J Cancer. 2005; 113 (2): 276-83. Cerca con Google

Thomas M, Pim D, Banks L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene. 1999; 18 (53): 7690-700. Review. Cerca con Google

Heideman DA, Steenbergen RD, van der Torre J, Scheffner M, Alemany R, Gerritsen WR, Meijer CJ, Snijders PJ, van Beusechem VW. Oncolytic adenovirus expressing a p53 variant resistant to degradation by HPV E6 protein exhibits potent and selective replication in cervical cancer. Mol Ther. 2005; 12 (6): 1083-90. Cerca con Google

Veldman T, Horikawa I, Barrett JC, Schlegel R. Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein. J Virol. 2001; 75 (9): 4467-72. Cerca con Google

Garnett TO, Duerksen-Hughes PJ. Modulation of apoptosis by human papillomavirus (HPV) oncoproteins. Arch Virol. 2006; 151 (12): 2321-35. Review. Cerca con Google

Felsani A, Mileo AM, Paggi MG. Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins. Oncogene. 2006; 25 (38): 5277-85. Review. Cerca con Google

Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. J Clin Sci (Lond). 2006; 110 (5): 525-41. Review. Cerca con Google

Longworth MS, Laimins LA. The binding of histone deacetylases and the integrity of zinc finger-like motifs of the E7 protein are essential for the life cycle of human papillomavirus type 31. J Virol. 2004; 78 (7): 3533-41. Cerca con Google

Duensing S, Duensing A, Lee DC, Edwards KM, Piboonniyom SO, Manuel E, Skaltsounis L, Meijer L, Münger K. Cyclin-dependent kinase inhibitor indirubin-3'-oxime selectively inhibits human papillomavirus type 16 E7-induced numerical centrosome anomalies. Oncogene. 2004; 23 (50): 8206-15. Cerca con Google

Park JS, Kim EJ, Kwon HJ, Hwang ES, Namkoong SE, Um SJ. Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem. 2000; 275 (10): 6764-9. Cerca con Google

Zwerschke W, Jansen-Dürr P. Cell transformation by the E7 oncoprotein of human papillomavirus type interactions with nuclear and cytoplasmic target proteins. Adv Cancer Res. 2000; 78: 1-29. Review. Cerca con Google

17. Knipe DM, Roizman B, Howley PM, Griffin D. Fields Virology. Fifth edition Lippincott Williams& Wilkins. 2007; Vol 2 (62): 2299-2310. Cerca con Google

Zur Hausen, H. Papillomavirus causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000; 92 (9): 690-8. Cerca con Google

Giroglou T, Florin L, Schäfer F, Streeck RE, Sapp M. Human papillomavirus infection requires cell surface heparan sulfate. J Virol. 2001; 75 (3): 1565-70. Cerca con Google

Culp TD, Budgeon LR, Christensen ND. Human papillomaviruses bind a basal extracellular matrix component secreted by keratinocytes which is distinct from a membrane-associated receptor. Virology. 2006; 347 (1): 147-59. Cerca con Google

Howley, P. M. and D. R. Lowy. Papillomaviruses and their replication. Fields Virology, Philadelphia (PA): Lippincott-Raven; 2001; 2197-2229. Cerca con Google

Sterling J, Stanley M, Gatward G, Minson T. Production of human papillomavirus type 16 virions in a keratinocyte cell line. J Virol. 1990; 64 (12): 6305-7. Cerca con Google

Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol. 2004; 4 (1): 46-54. Review. Cerca con Google

Middleton K, Peh W, Southern S, Griffin H, Sotlar K, Nakahara T, El-Sherif A, Morris L, Seth R, Hibma M, Jenkins D, Lambert P, Coleman N, Doorbar J. Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. J Virol. 2003; 77 (19): 10186-201. Cerca con Google

Becker KA, Florin L, Sapp C, Maul GG, Sapp M. Nuclear localization but not PML protein is required for incorporation of the papillomavirus minor capsid protein L2 into virus-like particles. J Virol. 2004; 78 (3): 1121-8. Cerca con Google

Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348 (6): 518-27. Cerca con Google

IARC Working Group. Human Papillomavirus. IARC Monographs on the evaluation of carcinogenic risk to humans. Lyon 2007; vol 90. International Agency for Research on Cancer. Cerca con Google

Termine N, Panzarella V, Falaschini S, Russo A, Matranga D, Lo Muzio L, Campisi G. HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988-2007). Ann Oncol. 2008; (10): 1681-90. Review. Cerca con Google

Bulkmans NW, Berkhof J, Bulk S, Bleeker MC, van Kemenade FJ, Rozendaal L, Snijders PJ, Meijer CJ; POBASCAM Study Group. High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer. 2007; 96 (9): 1419-24. Cerca con Google

Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007; 370 (9590): 890-907. Review. Cerca con Google

Muñoz N, Castellsagué X, de González AB, Gissmann L. HPV in the etiology of human cancer. Vaccine. 2006; 24 Suppl 3: S3/1-10. Review. Cerca con Google

Castellsagué X, Díaz M, de Sanjosé S, Muñoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders PJ, Meijer CJ, Bosch FX; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006; 98 (5): 303-15. Cerca con Google

Castellsagué X, Muñoz N. Cofactors in human papillomavirus carcinogenesis role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr. 2003; 31: 20-8. Review. Cerca con Google

Madeleine MM, Johnson LG, Smith AG, Hansen JA, Nisperos BB, Li S, Zhao LP, Daling JR, Schwartz SM, Galloway DA. Comprehensive analysis of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 loci and squamous cell cervical cancer risk. Cancer Res. 2008; 68 (9): 3532-9. Cerca con Google

Palefsky J. Human papillomavirus infection in HIV-infected persons. Top HIV Med. 2007; 15 (4): 130-3. Review. Cerca con Google

Del Mistro A, Chieco Bianchi L. HPV-related neoplasias in HIV-infected individuals. Eur J Cancer. 2001; (10): 1227-35. Review. Cerca con Google

Castle PE, Giuliano AR. Genital tract infections, cervical inflammation, and antioxidant nutrients assessing their roles as human papillomavirus cofactors. J Natl Cancer Inst Monogr. 2003; 31: 29-34. Review. Cerca con Google

Lillo F, Galli L, Lodini S, Taccagni G, Ferrari A, Origoni M. Extralesional detection and load of human papillomavirus DNA: a possible marker of preclinical tumor spread in cervical cancer. J Low Genit Tract Dis. 2008 ; 12 (3): 204-9. Cerca con Google

Sichero L, Ferreira S, Trottier H, Duarte-Franco E, Ferenczy A, Franco EL, Villa LL. High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. Int J Cancer. 2007; 120 (8): 1763-8. Cerca con Google

Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189 (1): 12-9. Cerca con Google

Parkin DM, Bray F. The burden of HPV-related cancers. Vaccine. 2006; 24 Suppl 3: S3/11-25. Review. Cerca con Google

Castellsague X, de Sanjose S, Aguado T. HPV and Cervical Cancer in the wored. 2007 report. Vaccine. 2007; 25 Suppl 3: C27/C219. Cerca con Google

Clifford G, Franceschi S, Diaz M, Muñoz N, Villa LL. HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine. 2006; 24 Suppl 3: S3/26-34. Review. Cerca con Google

Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Muñoz N. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2008; 26 Suppl 10: K1-16. Review. Cerca con Google

Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2002: incidence, mortality and prevalence worldwide. Lyon, France: International Agency for Research on Cancer, 2004. Cerca con Google

Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T Jr, Young N; Forum Group Members; Bethesda 2001 Workshop. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002; 287 (16): 2114-9. Review. Cerca con Google

Sherman ME, Wang SS, Wheeler CM, Rich L, Gravitt PE, Tarone R, Schiffman M. Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions. Cancer Epidemiol Biomarkers Prev. 2003; 12 (10): 1038-44. Cerca con Google

Koss Leopold G. Koss’ diagnostic Cytology and its Histopathologic Bases. 2006; Fifth edition, volume 1: 282-394. Cerca con Google

Hubbard RA. Human papillomavirus testing methods. Arch Pathol Lab Med. 2003; 127(8): 940-5. Review. Cerca con Google

Molijn A, Kleter B, Quint W, van Doorn LJ. Molecular diagnosis of human papillomavirus (HPV) infections. J Clin Virol. 2005; 32 Suppl 1: S43-51. Review. Cerca con Google

Castle PE, Lorincz AT, Mielzynska-Lohnas I, Scott DR, Glass AG, Sherman ME, Schussler JE, Schiffman M. Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible. J Clin Microbiol. 2002; 40(3): 1088-90. Cerca con Google

Manos, M. M., Ting, D. K. Wright, A. J. Lewis, T. R. Broker, and S. M. Wolinsky. Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells 1989; 7: 209-214. Cerca con Google

Jacobs MV, de Roda Husman AM, van den Brule AJ, Snijders PJ, Meijer CJ, Walboomers JM. Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. J Clin Microbiol. 1995; 33 (4): 901-5. Cerca con Google

Kleter B, van Doorn LJ, ter Schegget J, Schrauwen L, van Krimpen K, Burger M, ter Harmsel B, Quint W. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol. 1989; 153 (6): 1731-9. Cerca con Google

Iftner T, Villa LL. Human papillomavirus technologies. J Natl Cancer Inst Monogr. 2003; (31): 80-8. Review. Cerca con Google

Molden T, Kraus I, Karlsen F, Skomedal H, Nygård JF, Hagmar B. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev. 2005 Feb; 14 (2): 367-72. Cerca con Google

Benevolo M, Vocaturo A, Mottolese M, Mariani L, Vocaturo G, Marandino F, Sperduti I, Rollo F, Antoniani B, Donnorso RP. Clinical role of p16INK4a expression in liquid-based cervical cytology: correlation with HPV testing and histologic diagnosis. Am J Clin Pathol. 2008; 129 (4): 606-12. Cerca con Google

Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, De Marco L, Giorgi-Rossi P, Pontenani G, Rosso S, Sani C, Sintoni C, Segnan N, Zorzi M, Cuzick J, Rizzolo R, Ronco G; New Technologies for Cervival Cancer Screening (NTCC) Working Group. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 2008; 9 (10): 937-45. Cerca con Google

Stanley MA. Human papillomavirus vaccines. Rev Med Virol. 2006; 16(3): 139-49. Review. Cerca con Google

Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol Oncol. 2008; 109; Suppl 2: S15-21. Review. Cerca con Google

Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, Brown DR, Ferenczy A, Harper DM, Koutsky LA, Kurman RJ, Lehtinen M, Malm C, Olsson SE, Ronnett BM, Skjeldestad FE, Steinwall M, Stoler MH, Wheeler CM, Taddeo FJ, Yu J, Lupinacci L, Railkar R, Marchese R, Esser MT, Bryan J, Jansen KU, Sings HL, Tamms GM, Saah AJ, Barr E. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine. 2006; 24 (27-28): 5571-83. Cerca con Google

Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007 May 10; 356 (19): 1928-43. Cerca con Google

Ault KA; Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007; 369 (9576): 1861-8. Cerca con Google

Kulasingam SL, Kim JJ, Lawrence WF, Mandelblatt JS, Myers ER, Schiffman M, Solomon D, Goldie SJ; ALTS Group. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). J Natl Cancer Inst. 2006; 98 (2): 92-100. Cerca con Google

Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, Dalla Palma P, Del Mistro A, Folicaldi S, Gillio-Tos A, Nardo G, Naldoni C, Schincaglia P, Zorzi M, Confortini M, Cuzick J, and the NTCC Working Group. Human Papillomavirus testing and liquid-based cytology in primary cervical screening: results at recruitment from the NTCC randomized controlled trial. JNCI, 2006; 98: 765-74. Cerca con Google

Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, De Lillo M, Naldoni C, Pierotti P, Rizzolo R, Segnan N, Schincaglia P, Zorzi M, Confortini M, Cuzick J, and the NTCC Working Group. Human Papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncology, 2006; 7: 547-55. Cerca con Google

Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, Minucci D, Naldoni C, Rizzolo R, Schincaglia P, Volante R, Zappa M, Zorzi M, Cuzick J, Segnan N, and the NTCC Working Group. Results at recruitment from a randomized controlled trial comparing Human Papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. JNCI 2008; 100: 492-501. Cerca con Google

Nobre RJ, de Almeida LP, Martins TC. Complete genotyping of mucosal human papillomavirus using a restriction fragment length polymorphism analysis and an original typing algorithm. J Clin Virol. 2008; 42 (1): 13-21. Cerca con Google

Adriaan J. C. van den Brule. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol, 2002; 40 (3): 779-787. Cerca con Google

Del Mistro A, Salamanca HF, Trevisan R, Bertorelle R, Parenti A, Bonoldi E, Zambon P, Minucci D. Human papillomavirus typing of invasive cervical cancers in Italy. Infect Agent Cancer. 2006; 1: 9. Cerca con Google

Arbyn, M., F. Buntinx. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004; 96 (4): 280- Cerca con Google

Solomon D, Schiffman M, Tarone R; ALTS Study group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001; 93 (4): 293-9. Cerca con Google

Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D; 2006 ASCCP-Sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis. 2007; 11 (4): 201-22. Cerca con Google

Castle PE, Solomon D, Wheeler CM, Gravitt PE, Wacholder S, Schiffman M Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol. 2008; 46 (8): 595-604. Cerca con Google

Schiffman M, Wheeler CM, Dasgupta A, Solomon D, Castle PE; The ALTS Group. A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal papanicolaou smears. Am J Clin Pathol. 2005; 124 (5): 722-32. Cerca con Google

Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008; 26 Suppl 10: K29-41. Review. Cerca con Google

Castle PE, Solomon D, Schiffman M, Wheeler CM. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst. 2005. 97 (14):1066-71. Cerca con Google

Tornesello ML, Duraturo ML, Salatiello I, Buonaguro L, Losito S, Botti G, Stellato G, Greggi S, Piccoli R, Pilotti S, Stefanon B, De Palo G, Franceschi S, Buonaguro FM. Analysis of human papillomavirus type-16 variants in Italian women with cervical intraepithelial neoplasia and cervical cancer. J Med Virol. 2004; (1): 117-26. Cerca con Google

Hesselink AT, Bulkmans NW, Berkhof J, Lorincz AT, Meijer CJ, Snijders PJ. Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. J Clin Microbiol. 2006; 44 (10): 3680-5. Cerca con Google

Rousseau MC, Pereira JS, Prado JC, Villa LL, Rohan TE, Franco EL. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis. 2001;184 (12):1508-17. Cerca con Google

Carozzi FM, Del Mistro A, Confortini M, Sani C, Puliti D, Trevisan R, De Marco L, Tos AG, Girlando S, Palma PD, Pellegrini A, Schiboni ML, Crucitti P, Pierotti P, Vignato A, Ronco G. Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting. Am J Clin Pathol. 2005; 124 (5): 716-21. Cerca con Google

Download statistics

Solo per lo Staff dell Archivio: Modifica questo record